Nivolumab is a monoclonal antibody that binds to the PD-1 receptor on T cells and inhibits the interaction with the PD-L1 and PD-L2 ligands on cancer cells. Thus, nivolumab has immunostimulatory properties. The known side effects of this therapy include fatigue, skin rash, dysfunction of the thyroid gland and colitis, which are explained by the immunoregulatory mechanisms of the drug. Here we report on the case of a 58-year-old man with metastatic base of tongue carcinoma who developed de novo psoriasis triggered by nivolumab. The patient was treated for months with the diagnosis of a generalized mycosis. This case highlights the importance of vigilance for unexpected cutaneous side effects during immune stimulating therapy with checkpoint inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00105-017-4109-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiovascular Complications During Delivery Hospitalization in Patients With Psoriasis.
JACC Adv
January 2025
Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address:
Background: Psoriasis in pregnancy is associated with adverse maternal outcomes. However, there are limited data on this subject.
Objectives: The purpose of our study was to investigate the association between psoriasis and related cardiovascular complications during delivery.
Paradoxical Inflammatory Bowel Disease Induced by Golimumab in a Patient With Ankylosing Spondylitis: A Case Report and Systematic Review.
Cureus
January 2025
Faculty of Medicine, University of Hama, Hama, SYR.
Paradoxical reactions (PRs) to biologic medications, such as psoriasis, arthritis, and inflammatory bowel disease (IBD), have been increasingly recognized. The aim of reporting this case is to establish an association between golimumab and exacerbation or new (de novo) IBD in patients with axial spondyloarthritis (SpA). Our case involves a young patient with juvenile-onset ankylosing spondylitis (AS) who developed de novo IBD following golimumab therapy for active spinal disease.
View Article and Find Full Text PDF"Excluding Myself From What I Need the Most": Experiences of Loneliness in People With Inflammatory Arthritis: A Qualitative Study.
Int J Rheum Dis
January 2025
Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.
Objective: Despite advancements in pharmacological treatments, living with inflammatory arthritis (IA) (including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA)) can make it challenging to engage in social activities, which may increase the risk of loneliness. Although loneliness is predominantly prevalent in IA, its origin and impact on mental health status on daily life with IA remain unexplored. Therefore, the objective of this study was to describe the experiences of people with IA in relation to loneliness.
View Article and Find Full Text PDFWe present a case of a patient with longstanding psoriasis vulgaris who developed an atopic dermatitis-like eruption following long-term IL-17A inhibitor therapy. Following many years of excellent disease control with secukinumab and later ixekizumab, he developed a de novo eczematous eruption, which showed spongiotic dermatitis upon biopsy. The patient was successfully treated for both psoriasis and atopic dermatitis with upadacitinib, a Janus kinase inhibitor.
View Article and Find Full Text PDFIncidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus.
JAMA Dermatol
December 2024
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas.
Article Synopsis
- Autoimmune diseases like systemic lupus erythematosus (SLE) and psoriasis have been linked to a higher risk of atherosclerotic cardiovascular disease (ASCVD), but the impact of cutaneous lupus erythematosus (CLE) on ASCVD risk is uncertain.
- A study aimed to compare the incidence and prevalence of ASCVD among patients with CLE, SLE, and psoriasis against a control group without these diseases, utilizing data from a large health database.
- The results showed that individuals with CLE and SLE had significantly higher odds of developing ASCVD compared to the control group, but psoriasis did not show the same increased risk.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!